leadf
logo-loader
viewTetra Bio-Pharma

Tetra Bio-Pharma taps clinical research veteran Jean-Francois Boily to CFO position

Boily brings more than 15 years of industry experience to Tetra, including executive positions in clinical research organizations,

Boardroom with three people
Tetra has developed a pipeline of cannabinoid-based products for a range of medical conditions, including pain, inflammation and oncology

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) has named longtime clinical research executive Jean-Francois Boily its new CFO, the company announced Friday, effective September 14.

Boily brings more than 15 years of industry experience to Tetra, including executive positions in clinical research organizations, the core of the company’s research and development activities. He has worked at several pharmaceutical companies and built an excellent reputation in developing financial relationships, raising capital, satisfying financial obligations, ensuring record control, overseeing mergers and acquisitions and more, the company said.

"I look forward to working together with Jean-Francois to build Tetra into a successful pharmaceutical company,” CEO Guy Chamberland said in a statement. “His extensive experience in our sector, along with Nasdaq experience, is exactly what we need to ensure our growth."

READ: Tetra Bio-Pharma says Dania Scott has joined the company as its senior vice president of commercial strategy

Boily replaces Sabino Di Paola, who joined Tetra in 2019 and was instrumental in its graduation from the TSXV to the TSX.

"Sabino was dedicated to the growth of Tetra, leaving no stone unturned, to ensure we raised the capital needed,” Chamberland said. “On behalf of Tetra and the board of directors, we thank him for his financial expertise at a critical time in Tetra's evolution and wish him great success in his future endeavours.”

Tetra is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a FDA- and a Health Canada- approved clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.

The company has developed a pipeline of cannabinoid-based products for a range of medical conditions, including pain, inflammation and oncology.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Tetra Bio-Pharma

Price: - -

TSX-V:TBP
Market: TSX-V
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Tetra Bio-Pharma adds two experienced life sciences execs to its board,...

Tetra Bio-Pharma Inc. (TSX:TBP.TO) (OTCQB:TBPMF) Chairman of the Board Bill Cheliak tells Proactive the Ottawa-based group has added two new board members and has appointed a new COO. Cheliak says board members Dale Weil and Dr. Brent Norton, along with COO Dr. Graham Wood will be key to helping...

1 week, 4 days ago

2 min read